Table 1. Sociodemographic Characteristics, Clinical Features, Health Behaviors, and Adverse Health Outcomes for Survivors of Cisplatin-Treated Germ Cell Tumorsa.
| Characteristic | Patients, No. (%) | P valueb | ||
|---|---|---|---|---|
| Total population (N = 100) | Hearing loss (n = 54)a | No hearing loss (n = 46) | ||
| Age at initial TPS-1 assessment, median (range), y | 41 (20-61) | 43 (20-61) | 40 (21-61) | .19 |
| Age at TPS-2 assessment, median (range), y | 48 (25-67) | 50 (25-67) | 46 (27-67) | .23 |
| Time between TPS-1 and TPS-2, median (range), mo | 80 (44-99) | 83 (50-99) | 79 (44-99) | .69 |
| Race | ||||
| White | 94 (94) | 51 (94) | 43 (94) | >.99 |
| Other/unknownc | 6 (6) | 3 (6) | 3 (7) | |
| Marital status | ||||
| Not married | 26 (26) | 16 (30) | 10 (22) | .37 |
| Married/living as married | 74 (74) | 38 (70) | 36 (78) | |
| Educationd | ||||
| Not college graduate | 35 (35) | 26 (48) | 9 (20) | .01 |
| College/university graduate | 37 (37) | 18 (33) | 19 (41) | |
| Postgraduate level | 28 (28) | 10 (19) | 18 (39) | |
| Insurance | ||||
| Employer-based | 67 (67) | 35 (65) | 32 (70) | .29 |
| Spouse/parent | 16 (16) | 7 (13) | 9 (20) | |
| Military/Medicare/Medicaid/public program | 7 (7) | 6 (11) | 1 (2) | |
| Self-purchased/none/other/unknown | 10 (10) | 6 (11) | 4 (9) | |
| Employment | ||||
| Employed | 93 (93) | 50 (93) | 43 (94) | .29 |
| On disability | 1 (1) | 1 (2) | 0 | |
| Retired | 4 (4) | 3 (6) | 1 (2) | |
| Unemployed/student | 2 (2) | 0 | 2 (4) | |
| Job categoryd | ||||
| ISCO levels 1-2 | 22 (31) | 12 (31) | 10 (30) | .97 |
| ISCO levels 3-4 | 50 (69) | 27 (69) | 23 (70) | |
| Clinical features, health behaviors, adverse health outcomes | ||||
| Age at first GCT diagnosis, median (IQR), y | 30.9 (16- 53) | 31.6 (16- 53) | 30.3 (18-46) | .73 |
| Time since end of chemotherapy, median (IQR), y | 14.0 (4-31) | 14.6 (4-31) | 13.7 (5-30) | .49 |
| Chemotherapy | ||||
| Cumulative cisplatin dose, mean (range), mg/m2e | 332 (200-600) | 345 (260-600) | 317 (200-402) | .03 |
| Cisplatin dose group, mg/m2 | ||||
| <300 | 11 (11) | 5 (9) | 6 (13) | .12 |
| 300 | 54 (54) | 25 (46) | 29 (63) | |
| 301-400 | 6 (6) | 3 (6) | 3 (7) | |
| ≥400 | 29 (29) | 21 (39) | 8 (17) | |
| Chemotherapy regimend | ||||
| BEPx3 | 61 (61) | 29 (54) | 32 (70) | .49 |
| BEPx4 | 12 (12) | 8 (15) | 4 (9) | |
| EPx4 | 3 (3) | 2 (4) | 1 (2) | |
| Other | 24 (24) | 15 (28) | 9 (20) | |
| Family history of hearing lossd | 15 (18) | 10 (22) | 5 (13) | .31 |
| Noise exposured | 39 (48) | 23 (51) | 16 (43) | .48 |
| Tobacco use | ||||
| Former/current smoker | 27 (27) | 17 (32) | 10 (22) | .27 |
| Never smoked/not specified | 73 (73) | 37 (69) | 36 (78) | |
| Body mass indexf | 28 (19-46) | 27 (19-43) | 28 (20-46) | 0.52 |
| Physical activity: moderate (<6 METs) | 95 (95) | 51 (94) | 44 (96) | >.99 |
| Physical activity: vigorous (6+ METs) | 57 (57) | 28 (52) | 29 (63) | .26 |
| Sedentary h per wkd | 39.3 (6-107) | 35.0 (6-107) | 42.0 (8-92) | .62 |
| Diabetes | 1 (1) | 1 (2) | 0 | >.99 |
| Hypertension | 28 (28) | 20 (37) | 8 (17) | .03 |
| Hypercholesterolemia | 35 (35) | 25 (46) | 10 (22) | .01 |
| Psychosocial symptomsd | 34 (34) | 15 (28) | 19 (41) | .16 |
| Cognitive dysfunction | 9 (11) | 7 (15) | 2 (5) | .17 |
| Tinnitusd | 58 (58) | 43 (80) | 15 (33) | <.001 |
| Tinnitus handicap (Tinnitus Primary Function Questionnaire TPFQ)g | ||||
| Total score, median (range) (maximum: 100) | 17.9 (0-92) | 24.9 (0-92) | 4.7 (0-33) | .01 |
| Degree of handicap | ||||
| No handicap (0%-16%) | 22 (45) | 13 (36) | 9 (69) | .05 |
| Mild to moderate handicap (17%-42%) | 17 (35) | 13 (36) | 4 (31) | |
| Severe handicap (>42%) | 10 (20) | 10 (28) | 0 | |
Abbreviations: BEP, bleomycin, etoposide, and cisplatin; EP, etoposide and cisplatin; GCT, germ cell tumor; ISCO, International Standard Classification of Occupations; METs, metabolic equivalents; TPFQ, Tinnitus Primary Function Questionnaire; TPS-1, The Platinum Study-1; TPS-2, The Platinum Study-2.
Data are from TPS-2 assessments unless otherwise specified.
P values are unadjusted.
Other race includes Black or African American; Asian; American Indiana or Alaskan Native; Native Hawaiian or Other Pacific Islander; other, please specify; or in any combination with or without White.
Definitions and data availability for self-reported hearing loss, education, ISCO job category, chemotherapy regimens, family history of hearing loss, noise exposure, psychosocial symptoms, tinnitus, and others can be found in the eAppendix and eMethods in Supplement 1.
A total of 22 patients received 400 mg/m2 and 7 patients received more than 400 mg/m2 with a range of 402 to 600 mg/m2.
Body mass index is calculated as weight in kilograms divided by height in meters squared.
Only patients who self-reported tinnitus were asked to complete the TPFQ, with data unavailable for 3 of these patients.
The total population is shown in the second column, followed by those with self-reported hearing loss (third column) and those without self-reported hearing loss (fourth column).